or Try an Advanced Search...

    Intravenous Infusion Stocks List

    Symbol Grade Name % Change
    REGN C Regeneron Pharmaceuticals, Inc. 4.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Angiogenesis Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cardiovascular Disease Cartilage Cholesterol Clinical Development Clinical Research Colorectal Cancer Dermatitis Disorders Human Monoclonal Antibodies Immune Diseases Immunology Infectious Diseases

    Related ETFs - A few ETFs which own one or more of the above listed Intravenous Infusion stocks.

    Symbol Grade Name Weight
    IBBQ C Invesco Nasdaq Biotechnology ETF 8.16
    IBB C iShares Nasdaq Biotechnology Index Fund 8.14
    BBH D Market Vectors Biotech ETF 7.72
    BIB C ProShares Ultra Nasdaq Biotechnology 5.92
    PJP B PowerShares Dynamic Pharmaceuticals 5.57
    View all Intravenous Infusion ETFs...
    Compare ETFs
    Compare BBH to BIB Compare IBB to BBH Compare IBB to BIB

        Intravenous Infusion Stocks Recent News

        Date Stock Title
        May 2 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
        May 2 REGN Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 REGN Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
        May 2 REGN Regeneron falls after Q1 miss; announces $3B share buybacks
        May 2 REGN 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
        May 2 REGN Regeneron Earnings Miss; Biotech Giant's Stock Falls
        May 2 REGN Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook
        May 2 REGN Regeneron Reports First Quarter 2024 Financial and Operating Results
        May 1 REGN Regeneron Pharmaceuticals Q1 2024 Earnings Preview
        May 1 REGN Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
        Apr 30 REGN Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
        Apr 30 REGN Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
        Apr 29 REGN Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
        Apr 29 REGN Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
        Apr 29 REGN EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
        Apr 28 REGN 11 Oversold Growth Stocks to Buy Right Now
        Apr 25 REGN AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
        Related Industries: Biotechnology
        Related Stock Lists: Angiogenesis Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cardiovascular Disease Cartilage Cholesterol Clinical Development Clinical Research Colorectal Cancer Dermatitis Disorders Human Monoclonal Antibodies Immune Diseases Immunology Infectious Diseases
        Intravenous Infusion

        Browse All Tags